PMID- 32266131
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive 
      Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
PG  - 288
LID - 10.3389/fonc.2020.00288 [doi]
LID - 288
AB  - Purpose: Both 12 and 6 months of trastuzumab in combination with chemotherapy are 
      effective for HER2+ early-stage breast cancer. This meta-analysis was performed 
      to assess the effectiveness and the toxicity of the two durations. Methods and 
      Materials: We acquired relevant randomized controlled trials (RCTs) from PubMed, 
      the Cochrane Library, ScienceDirect, EMBASE, Ovid MEDLINE, Web of Science, 
      Scopus, and Google Scholar. Our endpoints included disease-free survival (DFS), 
      overall survival (OS), number of recurrences, mortality and early stopping of 
      trastuzumab, and adverse events (AEs). Results: We included five good-quality 
      studies. Both durations of trastuzumab were effective among women with HER2+ 
      early-stage breast cancer, but 12 months of trastuzumab appeared to have better 
      DFS [hazard ratio (HR) = 1.10, 95% confidence interval (CI): 0.99-1.23, P = 0.09] 
      and better OS than 6 months of trastuzumab (HR = 1.14, 95% CI: 0.99-1.32, P = 
      0.07). However, the 12 month group had more AEs, especially cardiac events [risk 
      ratio (RR) = 0.66, 95% CI: 0.56-0.77, P < 0.00001]. In our sub-analyses, the 12 
      months duration had better DFS among patients using trastuzumab concurrently than 
      the 6 months duration (HR = 1.23, 95% CI: 1.06-1.44, P = 0.006). Additionally, 
      the 12 months duration had superior OS in women with ER-negative breast cancer 
      (HR = 1.51, 95% CI: 1.10-2.08, P = 0.01) and patients treated with trastuzumab 
      concurrently than the 6 months duration (HR = 1.61, 95% CI: 1.13-2.29, P = 
      0.008). Conclusions: Twelve months was the standard duration of adjuvant 
      trastuzumab among patients with HER2+ early-stage breast cancer, with a tendency 
      toward superior survival. However, patients in the 12 month group had more 
      significant cardiac toxicity than those in the 6 month group.
CI  - Copyright (c) 2020 Deng, Du, Wang and Chen.
FAU - Deng, Huan
AU  - Deng H
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences, Hangzhou, China.
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, China.
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing, 
      China.
FAU - Du, Xianghui
AU  - Du X
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences, Hangzhou, China.
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, China.
AD  - Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang 
      Cancer Hospital, Hangzhou, China.
FAU - Wang, Li
AU  - Wang L
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Chen, Ming
AU  - Chen M
AD  - Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, 
      Hangzhou, China.
AD  - Department of Radiation Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences, Hangzhou, China.
AD  - Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, 
      Zhejiang Cancer Hospital, Hangzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20200320
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7098966
OTO - NOTNLM
OT  - RCTs
OT  - breast cancer
OT  - meta-analysis
OT  - optimal duration
OT  - trastuzumab
EDAT- 2020/04/09 06:00
MHDA- 2020/04/09 06:01
PMCR- 2020/01/01
CRDT- 2020/04/09 06:00
PHST- 2019/12/07 00:00 [received]
PHST- 2020/02/19 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2020/04/09 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00288 [doi]
PST - epublish
SO  - Front Oncol. 2020 Mar 20;10:288. doi: 10.3389/fonc.2020.00288. eCollection 2020.